Dr. Nanus on Trials Investigating Immunotherapy in RCC

Video

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses trials investigating immunotherapy regimens for patients with renal cell carcinoma (RCC).

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses trials investigating immunotherapy regimens for patients with renal cell carcinoma (RCC).

There are several phase III upfront randomized trials of immunotherapy that are interesting, says Nanus. One of the issues with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy), which has shown great efficacy as a treatment in the upfront setting, is the risk of immunologic side effects. It was seen that some of the trials with PD-1/PD-L1 inhibitors plus tyrosine kinase inhibitors may have less toxicity with similar efficacy. In the adjuvant setting, there are 3 or 4 adjuvant trials investigating this strategy.

In December 2017, the FDA granted a priority review to a supplemental biologics license application for the use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with RCC. This is based on the phase III CheckMate-214 trial, in which the combination reduced the risk of death by 32% compared with sunitinib (Sutent) for patients with metastatic RCC. The median overall survival was not reached with the combination versus 32.9 months with sunitinib (HR, 0.68; 99.8% CI, 0.49-0.95; P = .0003).

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,